Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $54,499 | $5,878,000 | $8,791,000 | $8,693,000 |
| Dep. & Amort. | $31,711 | $4,497,000 | $4,399,000 | $4,507,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | -$55,973 | -$5,189,000 | -$18,661,000 | $14,652,000 |
| Other Non-Cash | $9,329 | -$5,132,431 | $24,361,000 | -$14,122,000 |
| Operating Cash Flow | $39,566 | $53,569 | $18,890,000 | $13,730,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$49,280 | -$1,856,000 | -$927,000 | -$3,056,000 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$696 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $88 | $1,840,790 | -$49,000 | $287,000 |
| Investing Cash Flow | -$49,889 | -$15,210 | -$976,000 | -$2,769,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$881,000 | -$3,154,000 | $0 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$133,463 | -$8,050,000 | $0 | -$13,513,000 |
| Dividends Paid | -$480 | -$6,408,000 | -$67,000 | -$5,876,000 |
| Other Fin. Act. | -$5,462 | $15,232,542 | $2,360,000 | -$828,000 |
| Financing Cash Flow | -$139,405 | -$106,458 | -$861,000 | -$20,217,000 |
| Forex Effect | -$7,494 | $35,068 | -$1,908,000 | $2,665,000 |
| Net Chg. in Cash | -$157,221 | -$33,031 | $92,997,000 | $0 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $586,887 | $619,918 | $0 | $0 |
| End Cash | $429,666 | $586,887 | $92,997,000 | $0 |
| Free Cash Flow | $29,210 | $40,690 | $17,963,000 | $10,674,000 |